Fusion Pharmaceuticals Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Fusion Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q1 2024.
  • Fusion Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$33.7M, a 38.6% decline year-over-year.
  • Fusion Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$104M, a 13.4% decline year-over-year.
  • Fusion Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$94.9M, a 8.32% decline from 2022.
  • Fusion Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$87.6M, a 8.1% decline from 2021.
  • Fusion Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$81M, a 3.47% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$104M -$33.7M -$9.38M -38.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$94.9M -$28.2M -$3.56M -14.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-20
Q3 2023 -$91.3M -$17.3M +$6.76M +28.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$98.1M -$25.2M -$6.1M -32% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-07
Q1 2023 -$92M -$24.3M -$4.38M -22% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$87.6M -$24.6M -$7.38M -42.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-20
Q3 2022 -$80.2M -$24M -$4.58M -23.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$75.6M -$19.1M +$7.78M +29% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$83.4M -$19.9M -$2.38M -13.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$81M -$17.2M -$3.85M -28.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$77.2M -$19.4M -$9.44M -94.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$67.8M -$26.9M +$17.9M +40% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$85.6M -$17.5M -$7.31M -71.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$78.3M -$13.4M -$5.18M -63.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$73.2M -$9.99M -$9.4M -1582% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$63.8M -$44.7M -$41.3M -1194% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 -$22.5M -$10.2M -$6.29M -160% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 -$16.2M -$8.21M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$594K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$3.46M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-10
Q1 2019 -$3.93M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.